Zenas BioPharma (NASDAQ: ZBIO) insider transactions
In the twelve months to 10 November 2026, executives and directors of Zenas BioPharma reported 0 open-market sales and 17 open-market purchases of 605,613 shares ($11.4m), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 18 May 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +60,000 | $16.88 | 96,928 | Form 4 |
| 29 April 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +35,000 | $17.62 | 1,786,039 | Form 4 |
| 28 April 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +25,000 | $18.02 | 1,751,039 | Form 4 |
| 31 March 2026 | Lu Hongbo | Director | Open-market purchase | +3,768 | $18.63 | 426,736 | Form 4 |
| 31 March 2026 | Kiselak Tomas | Director | Open-market purchase | +150,000 | $20.00 | 2,359,025 | Form 4 |
| 31 March 2026 | Lu Hongbo | Director | Open-market purchase | +75,000 | $20.00 | 422,968 | Form 4 |
| 31 March 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +34,000 | $19.31 | 1,726,039 | Form 4 |
| 30 March 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +20,000 | $18.23 | 1,692,039 | Form 4 |
| 13 February 2026 | Allen Patricia L | Director | Open-market purchase | +4,160 | $26.36 | 19,860 | Form 4 |
| 12 February 2026 | Allen Patricia L | Director | Open-market purchase | +5,000 | $23.77 | 5,000 | Form 4 |
| 12 February 2026 | Allen Patricia L | Director | Open-market purchase | +5,700 | $24.34 | 10,700 | Form 4 |
| 12 February 2026 | Allen Patricia L | Director | Open-market purchase | +5,000 | $26.50 | 15,700 | Form 4 |
| 11 February 2026 | Lu Hongbo | Director | Open-market purchase | +25,985 | $22.50 | 347,968 | Form 4 |
| 5 February 2026 | Fox Jennifer A. | See Remarks | Grant or award | +1,592 | $13.35 | 1,592 | Form 4 |
| 5 February 2026 | Farmer Joseph L | See Remarks | Grant or award | +974 | $13.35 | 974 | Form 4 |
| 2 February 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +57,000 | $17.96 | 423,155 | Form 4 |
| 9 January 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +20,000 | $16.55 | 366,155 | Form 4 |
| 8 January 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +30,000 | $16.30 | 346,155 | Form 4 |
| 7 January 2026 | Moulder Leon O JR | Chief Executive Officer | Open-market purchase | +50,000 | $16.38 | 316,155 | Form 4 |
| 9 October 2025 | Enright Patrick G | Director | Open-market purchase | +105,265 | $19.00 | 1,832,669 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Zenas BioPharma page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.